Cargando…

CYP46A1-dependent and independent effects of efavirenz treatment

Cholesterol excess in the brain is mainly disposed via cholesterol 24-hydroxylation catalysed by cytochrome P450 46A1, a CNS-specific enzyme. Cytochrome P450 46A1 is emerging as a promising therapeutic target for various brain diseases with both enzyme activation and inhibition having therapeutic po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mast, Natalia, El-Darzi, Nicole, Petrov, Alexey M, Li, Young, Pikuleva, Irina A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713991/ https://www.ncbi.nlm.nih.gov/pubmed/33305262 http://dx.doi.org/10.1093/braincomms/fcaa180

Ejemplares similares

The normalizing effects of the CYP46A1 activator efavirenz on retinal sterol levels and risk factors for glaucoma in Apoj(−/−) mice
por: El-Darzi, Nicole, et al.
Publicado: (2023)

In Vitro Activation of Cytochrome P450 46A1 (CYP46A1) by Efavirenz-Related Compounds
por: Mast, Natalia, et al.
Publicado: (2019)

Brain Acetyl-CoA Production and Phosphorylation of Cytoskeletal Proteins Are Targets of CYP46A1 Activity Modulation and Altered Sterol Flux
por: Mast, Natalia, et al.
Publicado: (2021)

Brain sterol flux mediated by cytochrome P450 46A1 affects membrane properties and membrane-dependent processes
por: Petrov, Alexey M, et al.
Publicado: (2020)

CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease
por: Lerner, Alan J., et al.
Publicado: (2022)

Low-Dose Anti-HIV Drug Efavirenz Mitigates Retinal Vascular Lesions in a Mouse Model of Alzheimer’s Disease
por: El-Darzi, Nicole, et al.
Publicado: (2022)

Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1)
por: Mast, Natalia, et al.
Publicado: (2017)

Increased Acetylcholine Levels and Other Brain Effects in 5XFAD Mice after Treatment with 8,14-Dihydroxy Metabolite of Efavirenz
por: Mast, Natalia, et al.
Publicado: (2022)

The Interplay between Retinal Pathways of Cholesterol Output and Its Effects on Mouse Retina
por: Petrov, Alexey M., et al.
Publicado: (2019)

Quantitative characterizations of the cholesterol-related pathways in the retina and brain of hamsters
por: Mast, Natalia, et al.
Publicado: (2023)

N,N-Dimethyl-3β-hydroxycholenamide Reduces Retinal Cholesterol via Partial Inhibition of Retinal Cholesterol Biosynthesis Rather Than its Liver X Receptor Transcriptional Activity
por: El-Darzi, Nicole, et al.
Publicado: (2018)

Use of complementary cation and anion heavy-atom salt derivatives to solve the structure of cytochrome P450 46A1
por: White, Mark Andrew, et al.
Publicado: (2008)

Characterizations of Hamster Retina as a Model for Studies of Retinal Cholesterol Homeostasis
por: El-Darzi, Nicole, et al.
Publicado: (2021)

2-Hydroxypropyl-β-cyclodextrin mitigates pathological changes in a mouse model of retinal cholesterol dyshomeostasis
por: El-Darzi, Nicole, et al.
Publicado: (2022)

Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications
por: Pikuleva, Irina A., et al.
Publicado: (2021)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2019)

Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog
por: Shah, Manish B., et al.
Publicado: (2018)

Histone H3 Ser57 and Thr58 phosphorylation in the brain of 5XFAD mice
por: Anderson, Kyle W., et al.
Publicado: (2015)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz
por: Mardi, Parham, et al.
Publicado: (2022)

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
por: Zhang, Y, et al.
Publicado: (2010)

Efavirenz and neuropsychiatric effects
por: Dheda, Mukesh
Publicado: (2017)

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection
por: Meng, Xianmin, et al.
Publicado: (2015)

Quantification of Histone Deacetylase Isoforms in Human Frontal Cortex, Human Retina, and Mouse Brain
por: Anderson, Kyle W., et al.
Publicado: (2015)

Cholesterol crystal formation is a unifying pathogenic mechanism in the development of diabetic retinopathy
por: Hammer, Sandra S., et al.
Publicado: (2023)

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana
por: Maseng, Monkgomotsi J, et al.
Publicado: (2021)

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
por: Mukonzo, Jackson K., et al.
Publicado: (2014)

Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV
por: Hui, KH, et al.
Publicado: (2016)

The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana
por: Maseng, Monkgomotsi J., et al.
Publicado: (2022)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

Efavirenz, dysrhythmia and HIV
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]
Publicado: (2021)

Excitotoxicity increases the release of 24S-hydroxycholesterol via CYP46A1 activation
por: Sodero, Alejandro, et al.
Publicado: (2013)

Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice
por: Ali, Tahir, et al.
Publicado: (2021)

Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz
por: Larru, Beatriz, et al.
Publicado: (2014)

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin
por: Soeria-Atmadja, Sandra, et al.
Publicado: (2017)

Efavirenz: a decade of clinical experience in the treatment of HIV
por: Maggiolo, Franco
Publicado: (2009)

Treatment non-responsiveness in depression following Efavirenz administration
por: Das, Subhash, et al.
Publicado: (2020)

CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease
por: Boussicault, Lydie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8sc8v7lq8vtviu1d63fs5lbdu9